Symbols / SPRO $2.58 -0.39%
SPRO Chart
About
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 145.36M |
| Enterprise Value | 100.65M | Income | -43.84M | Sales | 40.55M |
| Book/sh | 0.47 | Cash/sh | 0.86 | Dividend Yield | — |
| Payout | 0.00% | Employees | 32 | IPO | — |
| P/E | — | Forward P/E | -2.32 | PEG | — |
| P/S | 3.58 | P/B | 5.49 | P/C | — |
| EV/EBITDA | -2.23 | EV/Sales | 2.48 | Quick Ratio | 3.74 |
| Current Ratio | 3.83 | Debt/Eq | 12.65 | LT Debt/Eq | — |
| EPS (ttm) | -0.79 | EPS next Y | -1.11 | EPS Growth | — |
| Revenue Growth | -59.60% | Earnings | 2026-03-26 | ROA | -29.77% |
| ROE | -95.30% | ROIC | — | Gross Margin | -52.19% |
| Oper. Margin | -134.67% | Profit Margin | -108.11% | Shs Outstand | 56.34M |
| Shs Float | 45.78M | Short Float | 1.24% | Short Ratio | 1.59 |
| Short Interest | — | 52W High | 3.22 | 52W Low | 0.51 |
| Beta | 1.53 | Avg Volume | 297.61K | Volume | 385.98K |
| Target Price | $4.00 | Recom | Hold | Prev Close | $2.59 |
| Price | $2.58 | Change | -0.39% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.00
Mean price target
2. Current target
$2.66
Latest analyst target
3. DCF / Fair value
$-2.34
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.66
Low
$4.00
High
$4.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-01-30 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-12-20 | down | Evercore ISI Group | Outperform → In-Line | $5 |
| 2024-12-02 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-18 | down | TD Cowen | Buy → Hold | — |
| 2024-11-15 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-11-04 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-10-03 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-06 | up | TD Cowen | Hold → Buy | — |
| 2024-08-06 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-04-04 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-09-05 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-08-14 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-07-20 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-04-10 | reit | HC Wainwright & Co. | — → Buy | $6 |
| 2022-09-26 | main | HC Wainwright & Co. | — → Buy | $6 |
- Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Large Decline in Short Interest - MarketBeat Sun, 15 Mar 2026 14
- SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal - Yahoo Finance hu, 29 May 2025 07
- A new pill for severe urinary tract infections moves closer to FDA review - Stock Titan Fri, 19 Dec 2025 08
- Insider Sale: Chief Operating Officer of $SPRO Sells 18,891 Shares - Quiver Quantitative hu, 05 Feb 2026 08
- Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround - Nasdaq ue, 19 Aug 2025 07
- Spero Therapeutics: Tebipenem’s FDA Path Supports A Speculative Buy (NASDAQ:SPRO) - Seeking Alpha Wed, 11 Feb 2026 08
- Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st Wed, 29 Oct 2025 07
- Earnings call transcript: Spero Therapeutics beats Q2 2025 forecasts, stock rises - Investing.com ue, 12 Aug 2025 07
- Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans? - Yahoo Finance Mon, 15 Dec 2025 08
- Spero Therapeutics Co-Founder Resigns From Board Roles - TipRanks Fri, 30 Jan 2026 08
- Spero Therapeutics (Nasdaq: SPRO) grants 90,000 RSUs to new employee - Stock Titan Fri, 28 Nov 2025 08
- Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update - GlobeNewswire hu, 13 Nov 2025 08
- Can ChatGPT Outperform the Market? Week 15 - HackerNoon Mon, 10 Nov 2025 08
- Spero Therapeutics - Additional Upside Potential Following Positive Phase 3 Results (SPRO) - Seeking Alpha Wed, 11 Jun 2025 07
- Trade Alert: CEO, CFO Of Spero Therapeutics Esther Rajavelu Has Sold Stock - simplywall.st Sat, 14 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 18652 | 44019 | — | Sale at price 2.36 per share. | KEUTZER TIMOTHY | Chief Operating Officer | — | 2026-02-06 00:00:00 | D |
| 1 | 87917 | 207484 | — | Sale at price 2.36 per share. | RAJAVELU ESTHER | Chief Executive Officer | — | 2026-02-06 00:00:00 | D |
| 2 | 46586 | 101175 | — | Sale at price 2.14 - 2.24 per share. | KEUTZER TIMOTHY | Chief Operating Officer | — | 2026-02-04 00:00:00 | D |
| 3 | 249000 | — | — | Stock Award(Grant) at price 0.00 per share. | RAJAVELU ESTHER | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 4 | 68000 | — | — | Stock Award(Grant) at price 0.00 per share. | KEUTZER TIMOTHY | Chief Operating Officer | — | 2026-02-02 00:00:00 | D |
| 5 | 18442 | 40572 | — | Sale at price 2.20 per share. | RAJAVELU ESTHER | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 6 | 40270 | 95440 | — | Sale at price 2.37 per share. | RAJAVELU ESTHER | Chief Executive Officer | — | 2025-11-07 00:00:00 | D |
| 7 | 6572 | 12947 | — | Sale at price 1.97 per share. | MAHADEVIA ANKIT | Director | — | 2025-08-28 00:00:00 | D |
| 8 | 1695 | 3339 | — | Sale at price 1.97 per share. | KEUTZER TIMOTHY | Chief Operating Officer | — | 2025-08-28 00:00:00 | D |
| 9 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | TREGONING KATHLEEN | Director | — | 2025-06-12 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | -541.21K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.10 | 0.00 | 0.00 |
| NormalizedEBITDA | -71.61M | 32.46M | -32.23M | -87.37M |
| TotalUnusualItems | -877.00K | -5.31M | -10.71M | 204.00K |
| TotalUnusualItemsExcludingGoodwill | -877.00K | -5.31M | -10.71M | 204.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -68.57M | 22.81M | -46.41M | -89.76M |
| ReconciledDepreciation | 2.00K | 367.00K | 869.00K | 646.00K |
| EBITDA | -72.48M | 27.15M | -42.94M | -87.17M |
| EBIT | -72.48M | 26.79M | -43.81M | -87.82M |
| NetInterestIncome | 4.74M | 3.94M | -1.50M | -1.59M |
| InterestExpense | 0.00 | 2.60M | 1.94M | |
| InterestIncome | 4.74M | 3.94M | 1.11M | 346.00K |
| NormalizedIncome | -67.69M | 27.57M | -35.70M | -89.96M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -68.57M | 22.81M | -46.41M | -89.76M |
| TotalExpenses | 99.88M | 69.95M | 79.15M | 91.04M |
| TotalOperatingIncomeAsReported | -73.36M | 21.48M | -42.20M | -87.97M |
| DilutedAverageShares | 54.04M | 52.99M | 37.59M | 30.90M |
| BasicAverageShares | 54.04M | 52.70M | 37.59M | 30.90M |
| DilutedEPS | -1.27 | 0.43 | -1.23 | -2.91 |
| BasicEPS | -1.27 | 0.43 | -1.23 | -2.91 |
| DilutedNIAvailtoComStockholders | -68.57M | 22.81M | -46.41M | -89.76M |
| NetIncomeCommonStockholders | -68.57M | 22.81M | -46.41M | -89.76M |
| NetIncome | -68.57M | 22.81M | -46.41M | -89.76M |
| NetIncomeIncludingNoncontrollingInterests | -68.57M | 22.81M | -46.41M | -89.76M |
| NetIncomeContinuousOperations | -68.57M | 22.81M | -46.41M | -89.76M |
| TaxProvision | 0.00 | 2.60M | 0.00 | |
| PretaxIncome | -68.57M | 25.40M | -46.41M | -89.76M |
| OtherIncomeExpense | -817.00K | -5.32M | -14.35M | -191.00K |
| OtherNonOperatingIncomeExpenses | 60.00K | -14.00K | -3.64M | -395.00K |
| SpecialIncomeCharges | -877.00K | -5.31M | -11.63M | 0.00 |
| OtherSpecialCharges | 3.58M | |||
| WriteOff | 0.00 | 5.31M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 5.31M | 0.00 | |
| RestructuringAndMergernAcquisition | 877.00K | 0.00 | 11.63M | 0.00 |
| GainOnSaleOfSecurity | 917.00K | 204.00K | ||
| NetNonOperatingInterestIncomeExpense | 4.74M | 3.94M | -1.50M | -1.59M |
| InterestExpenseNonOperating | 0.00 | 2.60M | 1.94M | |
| InterestIncomeNonOperating | 4.74M | 3.94M | 1.11M | 346.00K |
| OperatingIncome | -72.48M | 26.79M | -30.57M | -87.97M |
| OperatingExpense | 99.88M | 69.95M | 79.15M | 91.04M |
| OtherOperatingExpenses | -20.58M | -7.05M | -4.93M | -15.19M |
| ResearchAndDevelopment | 96.76M | 51.44M | 47.59M | 64.53M |
| SellingGeneralAndAdministration | 23.70M | 25.55M | 36.48M | 41.70M |
| GeneralAndAdministrativeExpense | 23.70M | 25.55M | 36.48M | 41.70M |
| OtherGandA | 10.52M | 10.23M | 16.05M | 19.46M |
| SalariesAndWages | 13.19M | 15.32M | 20.43M | 22.24M |
| TotalRevenue | 27.40M | 96.73M | 48.58M | 3.07M |
| OperatingRevenue | 27.40M | 96.73M | 48.58M | 3.07M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 54.59M | 53.00M | 52.46M | 32.39M |
| ShareIssued | 54.59M | 53.00M | 52.46M | 32.39M |
| TotalDebt | 4.30M | 5.54M | 6.65M | 7.33M |
| TangibleBookValue | 46.12M | 106.89M | 75.93M | 88.29M |
| InvestedCapital | 46.12M | 106.89M | 75.93M | 88.29M |
| WorkingCapital | 58.20M | 94.06M | 91.92M | 139.20M |
| NetTangibleAssets | 46.12M | 106.89M | 75.93M | 88.29M |
| CapitalLeaseObligations | 4.30M | 5.54M | 6.65M | 7.33M |
| CommonStockEquity | 46.12M | 106.89M | 75.93M | 88.29M |
| PreferredStockEquity | 3.00K | |||
| TotalCapitalization | 46.12M | 106.89M | 75.93M | 88.29M |
| TotalEquityGrossMinorityInterest | 46.12M | 106.89M | 75.93M | 88.29M |
| StockholdersEquity | 46.12M | 106.89M | 75.93M | 88.29M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 0.00 | -2.00K | |
| OtherEquityAdjustments | -2.00K | |||
| RetainedEarnings | -459.64M | -391.07M | -413.88M | -367.46M |
| AdditionalPaidInCapital | 505.71M | 497.91M | 489.76M | 455.72M |
| CapitalStock | 55.00K | 53.00K | 52.00K | 35.00K |
| CommonStock | 55.00K | 53.00K | 52.00K | 32.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 3.00K |
| TotalLiabilitiesNetMinorityInterest | 64.42M | 75.50M | 48.87M | 82.78M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 15.35M | 38.34M | 27.22M | 64.11M |
| OtherNonCurrentLiabilities | 87.00K | 96.00K | 48.55M | |
| DerivativeProductLiabilities | 576.00K | 23.61M | 12.43M | 802.00K |
| NonCurrentDeferredLiabilities | 12.22M | 10.82M | 9.74M | 8.79M |
| NonCurrentDeferredRevenue | 12.22M | 10.82M | 9.74M | 8.79M |
| LongTermDebtAndCapitalLeaseObligation | 2.55M | 3.83M | 4.96M | 5.97M |
| LongTermCapitalLeaseObligation | 2.55M | 3.83M | 4.96M | 5.97M |
| CurrentLiabilities | 49.07M | 37.15M | 21.65M | 18.67M |
| CurrentDeferredLiabilities | 22.12M | 27.11M | 10.37M | 1.86M |
| CurrentDeferredRevenue | 22.12M | 27.11M | 10.37M | 1.86M |
| CurrentDebtAndCapitalLeaseObligation | 1.75M | 1.72M | 1.69M | 1.36M |
| CurrentCapitalLeaseObligation | 1.75M | 1.72M | 1.69M | 1.36M |
| PayablesAndAccruedExpenses | 25.20M | 8.32M | 9.59M | 15.45M |
| CurrentAccruedExpenses | 17.72M | 6.56M | 8.97M | 14.35M |
| Payables | 7.48M | 1.76M | 617.00K | 1.10M |
| TotalTaxPayable | 174.00K | 387.00K | 0.00 | |
| IncomeTaxPayable | 174.00K | 387.00K | 0.00 | |
| AccountsPayable | 7.31M | 1.38M | 617.00K | 1.10M |
| TotalAssets | 110.54M | 182.39M | 124.80M | 171.07M |
| TotalNonCurrentAssets | 3.27M | 51.18M | 11.23M | 13.20M |
| OtherNonCurrentAssets | 153.00K | 435.00K | 5.74M | 5.64M |
| DuefromRelatedPartiesNonCurrent | 0.00 | 46.59M | ||
| NonCurrentAccountsReceivable | 46.59M | |||
| NetPPE | 3.11M | 4.16M | 5.49M | 7.56M |
| AccumulatedDepreciation | -3.62M | -3.62M | -3.25M | -2.88M |
| GrossPPE | 6.73M | 7.78M | 8.74M | 10.44M |
| Leases | 1.64M | 1.64M | 1.64M | 1.64M |
| ConstructionInProgress | 0.00 | |||
| OtherProperties | 4.45M | 5.49M | 6.46M | 7.87M |
| MachineryFurnitureEquipment | 646.00K | 646.00K | 646.00K | 932.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 107.28M | 131.21M | 113.57M | 157.87M |
| OtherCurrentAssets | 1.91M | 4.18M | 3.38M | 8.83M |
| PrepaidAssets | 8.83M | |||
| Receivables | 52.48M | 50.70M | 1.08M | 2.64M |
| OtherReceivables | 3.08M | 1.54M | 1.08M | 2.64M |
| DuefromRelatedPartiesCurrent | 49.39M | 49.15M | 0.00 | |
| TaxesReceivable | 361.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 52.89M | 76.33M | 109.11M | 146.40M |
| OtherShortTermInvestments | 0.00 | 33.82M | ||
| CashAndCashEquivalents | 52.89M | 76.33M | 109.11M | 112.58M |
| CashEquivalents | 52.26M | |||
| CashFinancial | 631.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -23.44M | -32.99M | -7.73M | -64.35M |
| IssuanceOfCapitalStock | 0.00 | 221.00K | 24.51M | 35.37M |
| IncomeTaxPaidSupplementalData | 99.00K | 2.21M | 0.00 | |
| EndCashPosition | 52.89M | 76.33M | 109.11M | 112.58M |
| BeginningCashPosition | 76.33M | 109.11M | 112.58M | 85.21M |
| ChangesInCash | -23.44M | -32.77M | -3.48M | 27.38M |
| FinancingCashFlow | 0.00 | 221.00K | -29.55M | 84.05M |
| CashFlowFromContinuingFinancingActivities | 0.00 | 221.00K | -29.55M | 84.05M |
| NetOtherFinancingCharges | -54.48M | 47.23M | ||
| ProceedsFromStockOptionExercised | 0.00 | 420.00K | 1.45M | |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 0.00 | 221.00K | 24.51M | 35.37M |
| CommonStockIssuance | 0.00 | 221.00K | 24.51M | 35.37M |
| InvestingCashFlow | 0.00 | 33.81M | 7.67M | |
| CashFlowFromContinuingInvestingActivities | 0.00 | 33.81M | 7.67M | |
| NetOtherInvestingChanges | 39.00K | |||
| NetInvestmentPurchaseAndSale | 0.00 | 33.81M | 7.63M | |
| SaleOfInvestment | 0.00 | 60.78M | 51.55M | |
| PurchaseOfInvestment | 0.00 | -26.97M | -43.91M | |
| NetPPEPurchaseAndSale | 39.00K | |||
| SaleOfPPE | 39.00K | |||
| OperatingCashFlow | -23.44M | -32.99M | -7.73M | -64.35M |
| CashFlowFromContinuingOperatingActivities | -23.44M | -32.99M | -7.73M | -64.35M |
| ChangeInWorkingCapital | 36.28M | -70.38M | 22.09M | 12.86M |
| ChangeInOtherWorkingCapital | -26.62M | 29.01M | 21.89M | 10.64M |
| ChangeInOtherCurrentLiabilities | -1.33M | -1.11M | -730.00K | -542.00K |
| ChangeInOtherCurrentAssets | 46.63M | -95.74M | -3.00K | -319.00K |
| ChangeInPayablesAndAccruedExpense | 16.88M | -1.27M | -5.86M | 2.06M |
| ChangeInAccruedExpense | 11.17M | -2.42M | -5.38M | 2.11M |
| ChangeInPayable | 5.71M | 1.15M | -484.00K | -53.00K |
| ChangeInAccountPayable | 5.93M | 761.00K | -484.00K | -53.00K |
| ChangeInTaxPayable | -213.00K | 387.00K | 0.00 | |
| ChangeInIncomeTaxPayable | -213.00K | 387.00K | 0.00 | |
| ChangeInPrepaidAssets | 2.27M | -799.00K | 5.24M | -2.81M |
| ChangeInReceivables | -1.54M | -461.00K | 1.55M | 3.83M |
| OtherNonCashItems | 1.04M | 969.00K | 3.28M | 2.41M |
| StockBasedCompensation | 7.79M | 7.93M | 9.12M | 9.43M |
| AssetImpairmentCharge | 0.00 | 5.31M | 635.00K | 0.00 |
| AmortizationOfSecurities | 0.00 | 13.00K | 251.00K | |
| DepreciationAmortizationDepletion | 2.00K | 367.00K | 869.00K | 646.00K |
| DepreciationAndAmortization | 2.00K | 367.00K | 869.00K | 646.00K |
| OperatingGainsLosses | 2.67M | -191.00K | ||
| GainLossOnInvestmentSecurities | -917.00K | -204.00K | ||
| NetForeignCurrencyExchangeGainLoss | 0.00 | 10.00K | 13.00K | |
| NetIncomeFromContinuingOperations | -68.57M | 22.81M | -46.41M | -89.76M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SPRO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|